home / stock / ewtx / ewtx quote
Last: | $17.48 |
---|---|
Change Percent: | -1.31% |
Open: | $18.57 |
Close: | $17.48 |
High: | $18.57 |
Low: | $17.41 |
Volume: | 637,355 |
Last Trade Date Time: | 05/13/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$17.48 | $18.57 | $17.48 | $18.57 | $17.41 | 637,355 | 05-13-2024 |
$18.33 | $19.1 | $18.33 | $19.99 | $17.955 | 1,139,404 | 05-10-2024 |
$20 | $19.65 | $20 | $20.83 | $19.39 | 1,026,485 | 05-09-2024 |
$20.89 | $20.81 | $20.89 | $21.6 | $20.365 | 686,786 | 05-08-2024 |
$21.23 | $20.37 | $21.23 | $21.6 | $20.02 | 777,039 | 05-07-2024 |
$20.34 | $19.3 | $20.34 | $20.44 | $18.98 | 587,300 | 05-06-2024 |
$19.52 | $19.74 | $19.52 | $20.12 | $19.44 | 545,136 | 05-03-2024 |
$19.29 | $19.13 | $19.29 | $19.55 | $18.5301 | 1,158,801 | 05-02-2024 |
$19.01 | $18.02 | $19.01 | $20.9 | $17.37 | 984,907 | 05-01-2024 |
$17.94 | $16.8 | $17.94 | $18.29 | $16.66 | 536,820 | 04-30-2024 |
$17.05 | $16.32 | $17.05 | $17.61 | $16.27 | 607,475 | 04-29-2024 |
$16.17 | $16.06 | $16.17 | $16.93 | $15.985 | 676,052 | 04-26-2024 |
$15.94 | $15.66 | $15.94 | $15.97 | $15.08 | 607,514 | 04-25-2024 |
$16.11 | $15.65 | $16.11 | $16.33 | $15.6 | 429,810 | 04-24-2024 |
$15.65 | $15.11 | $15.65 | $15.9 | $15.1 | 478,048 | 04-23-2024 |
$15.08 | $15.93 | $15.08 | $15.95 | $14.9 | 378,824 | 04-22-2024 |
$15.23 | $15.26 | $15.23 | $15.76 | $14.9 | 543,657 | 04-19-2024 |
$15.45 | $15.64 | $15.45 | $16.05 | $15.27 | 531,462 | 04-18-2024 |
$15.65 | $16.85 | $15.65 | $16.99 | $15.62 | 681,629 | 04-17-2024 |
$16.63 | $16.28 | $16.63 | $16.88 | $15.9 | 561,181 | 04-16-2024 |
News, Short Squeeze, Breakout and More Instantly...
Edgewise Therapeutics Inc. Company Name:
EWTX Stock Symbol:
NASDAQ Market:
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will be webcast live; a link for th...
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in thei...
– Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker – – Positive interim topline data for DUNE trial of sevasemten in Becker – – Expanded Phase 2 LYNX trial of sevas...